Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

orporation -- Licensing of Canadian Rights for SANCTURA XR to Allergan -- Licensing of Worldwide Rights for Pagoclone to Teva Corporate -- Issuance of U.S. Patent for SANCTURA XR -- Completion of Private Placement of $105 Million of Non-Recourse Notes

Financial Results

Total consolidated revenues for fiscal 2008 were $77.8 million, an increase of 18% from the $66.1 million reported for fiscal 2007. The primary components of revenue for fiscal 2008 were $43.8 million from the SANCTURA franchise, $16.6 million from sales of VANTAS, $13.2 million from sales of SUPPRELIN LA and $1.9 million from sales of DELATESTRYL(R).

Cost of product revenue for fiscal 2008 was $30.8 million, an increase of 111% from the $14.6 million reported for fiscal 2007. Cost of product revenue relates primarily of the costs to produce SANCTURA XR and royalty payments to Madaus and Supernus, all of which are reimbursed by Allergan, as well as the cost of product related to the sale of VANTAS, SUPPRELIN LA and DELATESTRYL.

Research and development expenses for fiscal 2008 were $25.0 million, a decrease of 40% from the $41.9 million reported for fiscal 2007. Marketing, general and administrative expenses for fiscal 2008 were $75.9 million, an increase of 26% from the $60.2 million reported for fiscal 2007.

Interest expense of $9.0 million for fiscal 2008 related to the Company's Convertible Notes and Non-recourse Notes.

Revenue for the quarter ended September 30, 2008 was $23.3 million, a decrease of 21% from the $29.5 million reported for the quarter ended September 30, 2007. The primary components of revenue for the quarter ended September 30, 2008 were $12.9 million from the SANCTURA franchise received from the Company's partner, $5.1 million from sales of VANTAS, $4.4 million from sales of SUPPRELIN LA, and $385,000 from sales of DELATESTRYL. The three- mo
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 This is a ... the Ammonium Bicarbonate industry in Global and China. The ... definitions, applications and industry chain structure. Global market analysis ... focus on history, developments, trends and competitive landscape of ... situation is also offered. , The report also focuses ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 AACC, ... better health through laboratory medicine, unveiled an updated brand ... laboratory professionals adapt to the changing healthcare environment and ... insight to physicians, so patients get the care they ... make up AACC,s membership play an essential role in ...
(Date:8/1/2014)... Aug. 1, 2014 Research and Markets ... Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism (SNP) ... of SNPs in the genome of various species. SNPs ... genotyping and analysis technology can analyze thousands of SNPs ...
(Date:8/1/2014)... Glencoe Software, Inc. is pleased ... ( http://glencoesoftware.com/data-inpress.html ), a suite of data ... into on-line publications.  The suite comprises Glencoe ... Photo - http://photos.prnewswire.com/prnh/20140731/132410   ... The DataViewer is a browser-based ...
Breaking Biology Technology:Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com 2Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com 3AACC Debuts Refreshed Brand Identity 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3
... 25 Tengion Inc., a clinical stage regenerative medicine company focused ... Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present ... 2, 2008 at 9:50 a.m. EST at The Palace Hotel in ... About Tengion , , ...
... RICHMOND, Va., Nov. 25 Insmed Inc. (Nasdaq: ... today that Dr. Geoffrey Allan, President and CEO of Insmed, ... View Conference on December 3, 2008, in New York. , ... conference is to better educate the investment community on the ...
... (Nasdaq: IDEV ) today announced its consolidated results,of ... September,30, 2008. The Company will host a conference call ... below). , The Company ... 18% from fiscal 2007 revenues of $66.1 million. For ...
Cached Biology Technology:Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference 2Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 2Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 3Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 4Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 5Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 6Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 7Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 8Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 9Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 10Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 11
(Date:7/31/2014)... study of bigeye tuna movements in the northwestern Atlantic ... Pelagics Research Center at the University of Massachusetts Amherst, ... wide geographical range with pronounced north-south movements from Georges ... high-use area off Cape Hatteras southwest of Bermuda for ... approach to study one of the most important commercial ...
(Date:7/31/2014)... tracing nearly 3,000 genes to the earliest common ... scientists have created an extensive "Tree of Lepidoptera" ... DNA sequencing. , Among the study,s more ... small moths than to large ones, which completely ... study also found that some insects once classified ...
(Date:7/31/2014)... that biomass burning burning forests to create ... slash-and-burn agriculture and wildfires figures into both ... the release of a new study by Stanford ... Jacobson, the degree of that contribution had never ... a paper published July 30 in the ...
Breaking Biology News(10 mins):Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4
... steady rise in autoimmune diseases such as multiple sclerosis ... factors could be the cause of this increase. One ... excessively germ-free environment may contribute to an increase in ... play a role in increasing autoimmune disease incidence. The ...
... a chronic relapsing inflammatory disorder of the intestinal ... in the developed world. Common symptoms include abdominal ... associated with debilitating clinical complications. Researchers from the ... important clue to the susceptibility of individuals to ...
... shown that termites can tell what sort of material their ... The findings may lead to improvements in the control of ... wooden blocks and specially designed blocks made of wood and ... the blocks containing the most wood ?even though they could ...
Cached Biology News:Parasite infection may benefit MS patients 2
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
E2F2 protein...
Biology Products: